tility of the enzyme-linked immunospot interferon-gamma-release assay to predict the risk of infection in kidney transplant recipients

Completed

• Conditions: Infection in kidney transplant recipients; CMV; BK virus; interferon; elispot; immunity; immunocompromised

• Registration Number: TCTR20210216004
• Lead Sponsor: Ramathibodi Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-02-16
• Study Completion: 2021-11-26
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

All kidney transplant recipients

Exclusion Criteria

Those who refused to join the study

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Infection 6 months Plasma CMV viral load, plasma BKV viral load, etc.

Secondary Outcome Measures

Name	Time	Method
Allograft rejection 6 months Creatinine, eGFR, DSA, allograft tissue pathology